O1P Stock Overview
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
RVL Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.003 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.003 |
| Beta | 0.90 |
| 1 Month Change | 0% |
| 3 Month Change | -25.00% |
| 1 Year Change | -99.73% |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| O1P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 2.5% |
| 1Y | -99.7% | -23.1% | 5.4% |
Return vs Industry: O1P underperformed the German Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: O1P underperformed the German Market which returned -0.9% over the past year.
Price Volatility
| O1P volatility | |
|---|---|
| O1P Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: O1P's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine O1P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 125 | Brian Markison | www.rvlpharma.com |
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc Fundamentals Summary
| O1P fundamental statistics | |
|---|---|
| Market cap | €30.76k |
| Earnings (TTM) | -€62.84m |
| Revenue (TTM) | €33.98m |
0.0x
P/S Ratio0.0x
P/E RatioIs O1P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O1P income statement (TTM) | |
|---|---|
| Revenue | US$36.92m |
| Cost of Revenue | US$6.53m |
| Gross Profit | US$30.39m |
| Other Expenses | US$98.66m |
| Earnings | -US$68.27m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 82.31% |
| Net Profit Margin | -184.91% |
| Debt/Equity Ratio | 353.7% |
How did O1P perform over the long term?
See historical performance and comparison